Pathogenetic Development, Diagnosis and Clinical Therapeutic Approaches for Liver Metastasis from Colorectal Cancer (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2025 Feb 14

PMID 39950314

Authors

Zhenhua Jin

Yin Li

Hao Yi

Menghui Wang

Chaofeng Wang

Shaokun Du

Wenjuan Zeng

Zhen Zong

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a prevalent malignancy and a significant proportion of patients with CRC develop liver metastasis (CRLM), which is a major contributor to CRC‑related mortality. The present review aimed to comprehensively examine the pathogenetic development and diagnosis of CRLM and the clinical therapeutic approaches for treatment of this disease. The molecular mechanisms underlying CRLM were discussed, including the role of the tumour microenvironment and epithelial‑mesenchymal transition. The present review also highlighted the importance of early detection and the current challenges in predicting the development of CRLM. Various treatment strategies were reviewed, including surgical resection, chemotherapy and immunotherapy, and the potential of novel therapies, such as selective internal radiation therapy and Traditional Chinese Medicine. Despite recent advancements in treatment options, the treatment of CRLM remains a therapeutic challenge due to the complexity of the liver microenvironment and the heterogeneity of CRC. The present review emphasized the need for a multidisciplinary approach and the integration of emerging therapies to improve patient outcomes.

References

Hecht J, Raman S, Chan A, Kalinsky K, Baurain J, Jimenez M . Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023; 8(2):100884. PMC: 10163149. DOI: 10.1016/j.esmoop.2023.100884. View

Zhang T, He W, Zi M, Song G, Yi D, Yang Y . Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine. Chin J Integr Med. 2018; 24(8):573-578. DOI: 10.1007/s11655-018-2980-0. View

Leblanc R, Peyruchaud O . Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016; 128(1):24-31. DOI: 10.1182/blood-2016-01-636399. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D . Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2016; 66(1):212-227. DOI: 10.1016/j.jhep.2016.07.009. View

Primrose J, Falk S, Finch-Jones M, Valle J, OReilly D, Siriwardena A . Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014; 15(6):601-11. DOI: 10.1016/S1470-2045(14)70105-6. View

Margonis G, Sergentanis T, Ntanasis-Stathopoulos I, Andreatos N, Tzanninis I, Sasaki K . Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis. Ann Surg. 2017; 267(6):1047-1055. DOI: 10.1097/SLA.0000000000002552. View

Donadon M, Hudspeth K, Cimino M, Di Tommaso L, Preti M, Tentorio P . Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival. J Gastrointest Surg. 2017; 21(8):1226-1236. DOI: 10.1007/s11605-017-3446-6. View

Akhurst R . From shape-shifting embryonic cells to oncology: The fascinating history of epithelial mesenchymal transition. Semin Cancer Biol. 2023; 96:100-114. PMC: 10883734. DOI: 10.1016/j.semcancer.2023.10.003. View

10.

Desch C, Benson 3rd A, Somerfield M, Flynn P, Krause C, Loprinzi C . Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005; 23(33):8512-9. DOI: 10.1200/JCO.2005.04.0063. View

11.

Feng W, Huang W, Chen J, Qiao C, Liu D, Ji X . CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. Theranostics. 2021; 11(6):2612-2633. PMC: 7806482. DOI: 10.7150/thno.52199. View

12.

Zhou H, Liu Z, Wang Y, Wen X, Amador E, Yuan L . Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Target Ther. 2022; 7(1):70. PMC: 8897452. DOI: 10.1038/s41392-022-00922-2. View

13.

Johnson D, Chee C, Wong W, Lam R, Tan I, Ma B . Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions. Cancer Treat Rev. 2024; 125:102700. DOI: 10.1016/j.ctrv.2024.102700. View

14.

van Duijnhoven F, Rovers J, Engelmann K, Krajina Z, Purkiss S, Zoetmulder F . Photodynamic therapy with 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: results from a phase I study. Ann Surg Oncol. 2005; 12(10):808-16. DOI: 10.1245/ASO.2005.09.005. View

15.

Kroemer M, Turco C, Spehner L, Viot J, Idirene I, Bouard A . Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. J Immunother Cancer. 2020; 8(2). PMC: 7684804. DOI: 10.1136/jitc-2020-001478. View

16.

Tang M, Zhang W, Qin W, Zou C, Yan Y, He B . Association between Oral Chinese Herbal Medicine and Recurrence and Metastasis in Patients with Stages II and III Colorectal Cancer: A Cohort Study in China. Evid Based Complement Alternat Med. 2022; 2022:8529395. PMC: 9666030. DOI: 10.1155/2022/8529395. View

17.

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y . Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. Mol Ther. 2017; 25(5):1248-1258. PMC: 5417843. DOI: 10.1016/j.ymthe.2017.03.010. View

18.

Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G . mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol. 2019; 24(5):516-525. PMC: 6469677. DOI: 10.1007/s10147-018-01393-8. View

19.

Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z . Single-cell and spatial analysis reveal interaction of FAP fibroblasts and SPP1 macrophages in colorectal cancer. Nat Commun. 2022; 13(1):1742. PMC: 8976074. DOI: 10.1038/s41467-022-29366-6. View

20.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View